This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is HealthEquity Stock a Buy Now Amid Strength in HSAs?
by Zacks Equity Research
HQY's strong quarterly results and solid top-line growth raise optimism about the stock.
ITGR Shares Gain on the Divestiture of Its Non-Medical Business Line
by Zacks Equity Research
Integer Holdings announces to divest its Electrochem business to Ultralife for $50 million in cash.
GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado
by Zacks Equity Research
GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
by Zacks Equity Research
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
Buy 3 Momentum Anomaly Stocks as Markets Bask in Economic Strength
by Supriyo Bose
JWN, UHS and PGR are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
3 Hospital Stocks to Buy With Strong Earnings Estimate Revisions
by Nalak Das
The U.S. hospital industry has been flying high in the past year. Three hospital stocks to buy are: HCA, THC, UHS.
PDCO Shares Gain Following New Deals to Boost Animal Health Business
by Zacks Equity Research
Patterson Companies announces to invest in two separate businesses to boost its animal health business.
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
by Zacks Equity Research
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
Tenet Adds $8B in Market Cap in 2024: Why it's Still a Healthy Buy
by Kaibalya Pravo Dey
Despite being close to its peak, THC remains a compelling buy due to its solid fundamentals, appealing valuation, and upward trend in earnings estimates.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
by Zacks Equity Research
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
MultiPlan Stock Falls Even After NRHA Rural Healthcare Deal
by Zacks Equity Research
MPLN and NRHA team up to empower rural healthcare providers with innovative technology and data-driven solutions, improving access, quality and affordability.
Encompass Health Opens 9th Hospital in SC: More in the Pipeline?
by Zacks Equity Research
This new facility is part of EHC's continued strategy to meet the rising demand for rehabilitative services.
Tactile Medical Stock Rises After Positive Flexitouch Trial Results
by Zacks Equity Research
TCMD announces a new study evaluating Flexitouch. The study reveals significant improvements in health-related quality of life and clinical outcomes.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
by Zacks Equity Research
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Reasons to Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.
ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall
by Zacks Equity Research
ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
by Zacks Equity Research
TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
by Zacks Equity Research
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
These Hospital Stocks Are Trouncing the S&P 500 This Year
by Bryan Hayes
The Zacks Rank has consistently identified big winners, regardless of which pocket of the market they may reside.
Cardinal Health Stock Likely to Gain From the Acquisition of ION
by Zacks Equity Research
CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.
ITGR Shares May Gain on the Completion of Irish Facility Expansions
by Zacks Equity Research
Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.